COUR Pharmaceuticals has been, as its newly-appointed President & CEO Dannielle Appelhans puts it, flying under the radar for a long time. COUR made a splash back in 2015, when it formed up around a biodegradable nanoparticle encapsulating gliadin proteins that proved to reverse the effects of gluten in animal models.

V.P. of R&D Tim Culp describes the rationale for in vivo CAR programs, what the company will be watching for from a safety standpoint, the development path ahead, and competition.

President-elect Donald Trump and Robert Kennedy, Jr. — his pick to head up the Department of Health and Human Services — were hot topics at the Jefferies …

Doctor Peter Vanderklish from Spinogenix talks about their advanced human trials in synaptic generation. Doctor Vanderklish, welcome to the program.

CEO Rajesh Devraj describes the company’s focus on membrane protein function and normalizing it with small molecules, in this case for cholestasis and cholangitis associated with liver diseases.

CEO Berndt Modig describes the science behind creating both immediate release capsuls and extended release tablets. Successfully developing an oral therapy could set Pharvaris apart.

While Anima has contributed to the scientific literature itself, with a growing list of peer-reviewed publications on protein synthesis monitoring and tRNA visualization, Slonim argues that relying solely on mining existing research isn’t enough.

Industry leaders reshaping the pharma world.